Global Markets for Contract Pharmaceutical Manufacturing, Research and Packaging

The global market for pharmaceutical and biopharmaceutical contract manufacturing, research and packaging was $219.9 billion in 2012. This market is estimated to reach $242.2 billion in 2013 and $374.8 billion by 2018, a five-year compound annual growth rate (CAGR) of 9.1%.

Report Includes

• An overview of the global market for contract pharmaceutical manufacturing, research, and packaging, with emphasis on the current and future outlook of the market and a comprehensive analysis of the overall pharmaceutical and biotechnology outsourcing industry.
• Analyses of global market trends, with data from 2011 and 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
• Examination of the effects on market growth of state-of-the-art packaging facilities as well as expensive research facilities and the capabilities of research organizations.
• Coverage of the market's need for outsourcing, the regulatory environment, and technological issues, including the latest trends and developments.
• Comprehensive company profiles of major players.

The global pharmaceutical contract manufacturing and contract research organizations revenue reached $196.5 billion in 2010, and it will further grow to $217.9 billion in 2011. The market is projected to reach $360.6 billion by 2016, increasing at a compound annual growth rate (CAGR) of 10.6%.

• Overall sales in the pharmaceutical contract manufacturing and contract research market were worth nearly $143 billion in 2007, which increased to an estimated $177 billion in 2009. By 2014, sales are projected to increase to nearly $299 billion, for a 5-year CAGR of 11.1%.
• The largest segment in the market, contract manufacture of OTC and nutraceuticals, was valued at $82 billion in 2007. This increased to an estimated $103 billion in 2009, and is projected to reach $177 billion in 2014, for a 5-year CAGR of 11.4%.
• Sales in the contract manufacture of bulk- and dosage-form drugs segment were worth $36 billion in 2007, and were to increase to nearly $44 billion in 2009. By 2014, they are projected to increase to $73 billion, for a 5-year CAGR of 10.8%..

• Worldwide revenue for contract manufacture of prescription drugs (dosage forms) for 2004 was $11.1 billion, which is projected to increase at a compound annual growth rate (CAGR) of 9.4%, reaching $22.5 billion by the end of 2011.
• Contract manufacture of over-the-counter and nutritional products worldwide is projected to reach $108.8 billion by 2011 increasing at a CAGR of 8.1%. Contract research revenues are projected to reach $24.3 billion by 2011, increasing from $17.3 billion in 2006 at a CAGR of 7.0%.
• Contract manufacturing in the bulk drug market had worldwide revenue of about $13.5 billion in 2004.

• Worldwide revenue for contract manufacturing and research for the pharmaceutical industry was estimated at $100 billion in 2004 and is expected to rise at an average annual growth rate (AAGR) of 10.8% to $168 billion in 2009.
• Contract manufacturing of prescription drugs for 2004 was estimated at $26.2 billion, and is expected to rise to $43.9 billion by end of 2009.
• Contract manufacturing of OTC and nutritional products is the largest and fastest growing segment, expected to rise at an AAGR of 11.3% to $102 billion by 2009.
• The contract research market is expected to reach $21.9 billion by 2009, rising at an AAGR of 8.6% from $ 14.5 billion in 2004.